A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35226
- Pfizer Investigational Site
-
-
Arizona
-
Litchfield Park, Arizona, United States, 85340
- Pfizer Investigational Site
-
-
California
-
Arcadia, California, United States, 91007-3462
- Pfizer Investigational Site
-
Beverly Hills, California, United States, 90210
- Pfizer Investigational Site
-
Costa Mesa, California, United States, 92626
- Pfizer Investigational Site
-
Costa Mesa, California, United States, 92627
- Pfizer Investigational Site
-
Encino, California, United States, 91316
- Pfizer Investigational Site
-
Escondido, California, United States, 92025
- Pfizer Investigational Site
-
Murrieta, California, United States, 92562
- Pfizer Investigational Site
-
National City, California, United States, 91950
- Pfizer Investigational Site
-
Newport Beach, California, United States, 92660-2452
- Pfizer Investigational Site
-
Orange, California, United States, 92868
- Pfizer Investigational Site
-
Pasadena, California, United States, 91106
- Pfizer Investigational Site
-
Redlands, California, United States, 92374
- Pfizer Investigational Site
-
San Diego, California, United States, 92108
- Pfizer Investigational Site
-
San Diego, California, United States, 92103
- Pfizer Investigational Site
-
Sherman Oaks, California, United States, 91403
- Pfizer Investigational Site
-
Temecula, California, United States, 92591
- Pfizer Investigational Site
-
Upland, California, United States, 91786
- Pfizer Investigational Site
-
Wildomar, California, United States, 92595
- Pfizer Investigational Site
-
-
Colorado
-
Denver, Colorado, United States, 80239
- Pfizer Investigational Site
-
-
Connecticut
-
Hamden, Connecticut, United States, 06518
- Pfizer Investigational Site
-
Norwich, Connecticut, United States, 06360
- Pfizer Investigational Site
-
-
Florida
-
Altamonte Springs, Florida, United States, 32701
- Pfizer Investigational Site
-
Ft. Myers, Florida, United States, 33912
- Pfizer Investigational Site
-
Jacksonville, Florida, United States, 32216
- Pfizer Investigational Site
-
Maitland, Florida, United States, 32751
- Pfizer Investigational Site
-
Miami, Florida, United States, 33126
- Pfizer Investigational Site
-
Miami, Florida, United States, 33143
- Pfizer Investigational Site
-
Orange City, Florida, United States, 32763
- Pfizer Investigational Site
-
Orlando, Florida, United States, 32806
- Pfizer Investigational Site
-
South Miami, Florida, United States, 33143
- Pfizer Investigational Site
-
West Palm Beach, Florida, United States, 33407
- Pfizer Investigational Site
-
-
Georgia
-
Atlanta, Georgia, United States, 30308
- Pfizer Investigational Site
-
Atlanta, Georgia, United States, 30328
- Pfizer Investigational Site
-
Marietta, Georgia, United States, 30060
- Pfizer Investigational Site
-
-
Illinois
-
Libertyville, Illinois, United States, 60048
- Pfizer Investigational Site
-
Naperville, Illinois, United States, 60563
- Pfizer Investigational Site
-
Park Ridge, Illinois, United States, 60068
- Pfizer Investigational Site
-
-
Indiana
-
Greenwood, Indiana, United States, 46143
- Pfizer Investigational Site
-
Terre Haute, Indiana, United States, 47802
- Pfizer Investigational Site
-
-
Kansas
-
Overland Park, Kansas, United States, 66212
- Pfizer Investigational Site
-
Prairie Village, Kansas, United States, 66206
- Pfizer Investigational Site
-
Wichita, Kansas, United States, 67207
- Pfizer Investigational Site
-
-
Kentucky
-
Owensboro, Kentucky, United States, 42301
- Pfizer Investigational Site
-
-
Louisiana
-
Lake Charles, Louisiana, United States, 70601
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21208
- Pfizer Investigational Site
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Pfizer Investigational Site
-
Boston, Massachusetts, United States, 02135
- Pfizer Investigational Site
-
Fall River, Massachusetts, United States, 02721
- Pfizer Investigational Site
-
Haverhill, Massachusetts, United States, 01830
- Pfizer Investigational Site
-
Pittsfield, Massachusetts, United States, 01201
- Pfizer Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68131
- Pfizer Investigational Site
-
-
Nevada
-
Las Vegas, Nevada, United States, 89146
- Pfizer Investigational Site
-
-
New Hampshire
-
Nashua, New Hampshire, United States, 03060
- Pfizer Investigational Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Pfizer Investigational Site
-
-
New York
-
Bronx, New York, United States, 10467
- Pfizer Investigational Site
-
Brooklyn, New York, United States, 11235
- Pfizer Investigational Site
-
New York, New York, United States, 10023
- Pfizer Investigational Site
-
New York, New York, United States, 10024
- Pfizer Investigational Site
-
New York, New York, United States, 10128-1708
- Pfizer Investigational Site
-
Rochester, New York, United States, 14618
- Pfizer Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, United States, 27607
- Pfizer Investigational Site
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Pfizer Investigational Site
-
Dayton, Ohio, United States, 45408
- Pfizer Investigational Site
-
Toledo, Ohio, United States, 43623
- Pfizer Investigational Site
-
Toledo, Ohio, United States, 43609
- Pfizer Investigational Site
-
-
Oklahoma
-
Bethany, Oklahoma, United States, 73008
- Pfizer Investigational Site
-
Oklahoma City, Oklahoma, United States, 73103
- Pfizer Investigational Site
-
Oklahoma City, Oklahoma, United States, 73116
- Pfizer Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Pfizer Investigational Site
-
Salem, Oregon, United States, 97301
- Pfizer Investigational Site
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18104
- Pfizer Investigational Site
-
Media, Pennsylvania, United States, 19063
- Pfizer Investigational Site
-
Norristown, Pennsylvania, United States, 19401
- Pfizer Investigational Site
-
Philadelphia, Pennsylvania, United States, 19139
- Pfizer Investigational Site
-
-
Rhode Island
-
Lincoln, Rhode Island, United States, 02865
- Pfizer Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, United States, 29201
- Pfizer Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, United States, 38119
- Pfizer Investigational Site
-
Memphis, Tennessee, United States, 38134
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78756
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75231
- Pfizer Investigational Site
-
Dallas, Texas, United States, 75230
- Pfizer Investigational Site
-
DeSoto, Texas, United States, 75115
- Pfizer Investigational Site
-
Houston, Texas, United States, 77008
- Pfizer Investigational Site
-
Houston, Texas, United States, 77074
- Pfizer Investigational Site
-
Lake Jackson, Texas, United States, 77566
- Pfizer Investigational Site
-
San Antonio, Texas, United States, 78229
- Pfizer Investigational Site
-
-
Vermont
-
Woodstock, Vermont, United States, 05091
- Pfizer Investigational Site
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- Pfizer Investigational Site
-
-
Washington
-
Seattle, Washington, United States, 98104
- Pfizer Investigational Site
-
-
Wisconsin
-
Middleton, Wisconsin, United States, 53562
- Pfizer Investigational Site
-
Waukesha, Wisconsin, United States, 53188-1660
- Pfizer Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must have completed all phases of one of the four preceding double-blind GAD studies.
- Female must continue to use adequate birth control methods and have a negative serum pregnancy test within 14 days prior to starting open label treatment.
Exclusion Criteria:
- Subjects who experienced a serious adverse event during the preceding double-blind efficacy study that was judged to be related to study medication by the investigator or the sponsor's medical monitor.
- Individuals who have an ongoing, unresolved, clinically significant medical problem that, in the judgment of the investigator or the sponsor's medical monitor, would make it unsafe for the subject to participate in the study.
- Serious suicidal risk per the clinical investigators's judgement.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The nature, incidence, and duration of adverse events monitored throughout the study by physical exam
Time Frame: Screening, Wk 25 & Wk 52/EOT
|
Screening, Wk 25 & Wk 52/EOT
|
|
Electrocardiogram will be performed at screening and during follow up visits to assess the safety and tolerability of the compound in terms of clinically significant cardiovascular changes
Time Frame: Screening, Wk 4, Wk 25, Wk 52/EOT
|
Screening, Wk 4, Wk 25, Wk 52/EOT
|
|
The Columbia Suicide Severity Rating scale will be used to assess any suicide related adverse events
Time Frame: As needed
|
As needed
|
|
The nature, incidence, and duration of adverse events monitored throughout the study by vital signs evaluation at each visit, weight measurements and clinical laboratory monitoring periodically
Time Frame: Screening, Baseline, Wk 4, Wk 12, Wk 25, Wk 38, & Wk 52/EOT
|
Screening, Baseline, Wk 4, Wk 12, Wk 25, Wk 38, & Wk 52/EOT
|
|
All discontinuations due to adverse events will be reviewed throughout the trial to assess the safety and tolerability of the compound
Time Frame: Weekly
|
Weekly
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The Hamilton Rating Scale for Anxiety (HAM-A) will be used to assess symptoms of Generalized Anxiety Disorder (GAD) over a one year time period.
Time Frame: Baseline, Wk 12, Wk 25, Wk 38, Wk 51 & Wk 52/EOT
|
Baseline, Wk 12, Wk 25, Wk 38, Wk 51 & Wk 52/EOT
|
|
The Clinical Global Impression of Severity (CGI-S), and the Daily Diary (DD) will also be used to assess symptoms of GAD over a one year time period.
Time Frame: Baseline, Wk 51 & Wk 52/EOT
|
Baseline, Wk 51 & Wk 52/EOT
|
|
The Health Care Utilization Questionnaire will be utilized to assess overall Health Care over a one year time period.
Time Frame: Baseline, Wk 12, Wk 25, Wk 38 & Wk 51
|
Baseline, Wk 12, Wk 25, Wk 38 & Wk 51
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- A5361022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.